Dr. Harriet B. Eldredge-Hindy

Dr. Charlotte Rivers is a board-certified radiation oncologist specializing in the treatment of central nervous system, hematological, and skin cancers. She is experienced in the use of Gamma Knife radiosurgery for the treatment of brain metastases, as well as other conditions including meningiomas, arteriovenous malformations, acoustic neuromas, and trigeminal neuralgia. Dr. Rivers serves as a member of the multi-disciplinary central nervous system team, and works closely with neuro-oncology and neurosurgery in the treatment of patients with primary brain tumors. She also works in coordination with the hematology teams to provide total body irradiation (TBI) for both adult and pediatric patients needing bone marrow transplants.Dr. Rivers has published clinical research in the field of Gamma Knife radiosurgery which has been presented at several national and international conferences. She joined the team at MUSC in 2019, and is happy to be back in her home state to help bring the best care possible to the people of South Carolina. She is passionate about teaching and is very involved in resident education. Dr. Rivers is highly rated in 30 conditions, according to our data. Her clinical expertise encompasses Metastatic Brain Tumor, Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), Astrocytoma, and Gamma Knife Radiosurgery. Dr. Rivers is currently accepting new patients.

Joseph Jenrette-Iii is a Radiation Oncologist practicing medicine in Charleston, South Carolina. Dr. Jenrette-Iii is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Meningioma, Posterior Fossa Tumor, Acoustic Neuroma, and Astrocytoma.

Bhisham Chera, M.D., is a board-certied radiation oncologist, Vice Chairman for Safety and Quality Assurance in the Department of Radiation Oncology, and the Wendy \& Keith Wellin Endowed Chair in Radiation Oncology. His primary clinical emphasis is in the treatment of head and neck, and skin cancers.Dr. Chera's academic interests are in head and neck oncology and health care quality and safety improvement. He is nationally and internationally known for his pioneering work in evaluating reduced intensity radiation and chemotherapy treatments for patients with human papillomavirus (HPV) associated with throat cancers. He has also co-invented a blood-based biomarker for HPV-associated cancers.As of 2022, Dr. Chera has published over 100 manuscripts, ten book chapters, presented his research at over 100 national meetings, and has given 70 invited talks. His contributions to the field of patient safety and quality improvement include 22 publications, membership on the Radiation Oncology Health Advisory Committee, and serving as an international expert for the International Atomic Energy Agency. Dr. Chera is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Laryngeal Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Throat Cancer, and Sinus Cancer. Dr. Chera is currently accepting new patients.